Related by context. All words. (Click for frequent words.) 63 NIH CPSI 61 International Prostate Symptom 61 HAM D# 61 nasal symptom 61 Score DAS 61 Dyspnea 61 mcg QD 60 Severity Scale 60 Crohn Disease Activity 60 MADRS score 60 oxycodone CR 60 Ishak fibrosis score 60 TNSS 60 Main Outcome Measures 60 Orthostatic Hypotension 59 Score IPSS 59 Symptom Severity 59 Stress Incontinence 59 Rating Scale MADRS 59 CDAI score 59 Ocular Surface Disease 59 Severity Index 59 WOMAC scores 59 Index CDAI 59 Psoriasis Area 58 Symptom Scale 58 pain subscale 58 Global Impression CGI 58 Brief Psychiatric 58 Severity Index PASI 58 Ischemic Stroke 58 cough dyspnea 58 IBDQ 58 Statistically Significant 58 Generalized Anxiety Disorder 58 albumin excretion rate 57 Subclinical 57 Secondary Endpoints 57 Brief Pain 57 subscores 57 Fracture Risk 57 ST Segment Elevation 57 PANSS 57 Primary Endpoint 57 SGOT 57 Treated Patients 57 UPDRS motor 57 Stomatitis 57 nausea somnolence 57 Rating Scale BPRS 57 Lower Limb 57 Montgomery Asberg Depression 57 HDRS 57 Montgomery Åsberg Depression 57 aspartate aminotransferase 57 Severity MSCS score 57 abdominal pain abdominal discomfort 57 liver histology 57 Health Assessment Questionnaire 57 Relapsing Remitting Multiple Sclerosis 57 Unified Parkinson Disease 56 lopinavir r arm 56 Abdominal Pain 56 headache abdominal pain 56 Visual Analog 56 hip BMD 56 Main Outcome Measure 56 IRLS score 56 Epworth Sleepiness Scale 56 Sleep Disturbance 56 UPDRS 56 PASI scores 56 Beta Blockers 56 Showed Significant 56 Respiratory Symptoms 56 Functional Assessment 56 Endothelial Function 56 Ejection Fraction 56 dyspnoea 56 rhinorrhea 56 DAS# CRP 56 ADHD Rating Scale 56 Assessment Questionnaire 56 Patients Receiving 56 Knee Osteoarthritis 56 NYHA functional class 56 serum cortisol 56 Claudication 56 Erythema 56 MCyR 56 BPH Symptom Score 56 Proteinuria 56 lumbar spine BMD 56 Symptom Checklist 56 Fungal Infections 56 Peripheral Arterial 56 Dysmenorrhea 56 pulmonary capillary wedge 56 MADRS 56 SGRQ 56 Depressive Symptoms 56 Prophylactic Treatment 56 Subscale 56 VFQ 55 Osteoarthritis Pain 55 Double Blind Randomized 55 conjunctival hyperemia 55 clinically meaningful improvement 55 rhinoconjunctivitis 55 bronchial hyperresponsiveness 55 Hypercholesterolemia 55 salmeterol fluticasone 55 Functional Capacity 55 Differential Diagnosis 55 Postoperative 55 PANSS scores 55 nausea photophobia 55 mmHg diastolic 55 SGPT 55 Hyperlipidemia 55 Pediatric Patients 55 clinically evaluable patients 55 Symptom severity 55 Nebulized 55 hematologic parameters 55 elevated transaminases 55 Scale PANSS 55 Nonspecific 55 Negative Syndrome 55 mucosal inflammation 55 Ascites 55 lumbar spine bone 55 multivariable adjusted 55 Symptom 55 See CLINICAL PHARMACOLOGY 55 subscale scores 55 Myalgia 55 HADS 55 Kidney Function 55 Negative Symptoms 55 Endothelial function 55 Oral Fingolimod 55 QIDS SR 55 Significant Improvements 55 alanine aminotransferase ALT 55 gastroduodenal 55 Meta Analysis 55 Visual Analog Scale 55 Tiotropium 55 Chronic Sinusitis 55 ALT elevation 55 overactive bladder symptoms 55 enthesitis 55 Distress Scale 55 YMRS 55 Depressive symptoms 55 PREZISTA r arm 55 severe exacerbations 54 Cognitive Impairment 54 Elderly Patients 54 HOMA IR 54 symptom severity 54 p = NS 54 Pain Intensity 54 Infarction 54 collagenous colitis 54 Comorbidities 54 alanine aminotransferase 54 P ≤ 54 CDAI 54 Atopic Dermatitis 54 Improves Outcomes 54 WOMAC pain 54 Rating Scale UPDRS 54 Rheumatoid 54 Non Responders 54 Fibromyalgia Impact Questionnaire 54 Y BOCS 54 Lower Extremity 54 epistaxis 54 bothersome symptom 54 #.#/#.# mmHg [001] 54 PANSS total 54 Neuropsychiatric Inventory 54 Cystatin C 54 abdominal pain flatulence 54 Thrombotic 54 ACR# ACR# 54 Diagnostic Criteria 54 generalized edema 54 Expanded Disability Status 54 PRODUCT SALES 54 CI -#.# 54 -#.# ± [002] 54 ADHD RS 54 hypophosphatemia 54 receiving golimumab 54 Heritability 54 Dyspepsia 54 Score TOS 54 Post Operative 54 thrombocytosis 54 imipramine Tofranil 54 Demonstrated Significant 54 Nonsurgical 54 Heart Failure Patients 54 leukocyte counts 54 epigastric pain 54 Panic Disorder 54 Severity Score 54 aspartate aminotransferase AST 54 Somnolence 54 urinary N telopeptide 54 Lung Function 54 arthralgias 54 Skin sterol 54 Stress Induced 54 Evaluable 53 Antipsychotic 53 coronary stenosis 53 Abnormal Involuntary Movement 53 Cilostazol 53 Significantly Improved 53 artery stenosis 53 Microalbuminuria 53 phosphorylated tau 53 Danazol 53 Pulsatile 53 Disease Activity 53 Ischemic 53 Cognitive Dysfunction 53 8mg/kg 53 Global Impression 53 Postherpetic Neuralgia 53 Chronic Bronchitis 53 Visual Analogue Scale VAS 53 HAMD 53 dysuria 53 Combo Therapy 53 fatigue nausea vomiting 53 Electrodiagnostic 53 OSDI 53 proctitis 53 glycosylated hemoglobin HbA1c 53 Prolongs Survival 53 Adult ADHD 53 bronchopulmonary 53 Nocturia 53 tipranavir r 53 Global Impression Severity 53 Timed Walk 53 rhinitis sinusitis 53 interobserver 53 UPDRS Part III 53 eNO 53 x ULN 53 mTSS 53 Fatty Liver 53 Mitral Regurgitation 53 ug kg 53 Urinary Tract Infections 53 Symptom Relief 53 bivalirudin monotherapy 53 tissue oxygenation 53 IRLS 53 pruritis 53 Chronic Illness Therapy 53 C Reactive Protein 53 Prostate Cancer Recurrence 53 Partial Response 53 paresthesias 53 Hemodialysis Patients 53 ADCS CGIC 53 Platelet Function 53 neutropaenia 53 Chronic Prostatitis 53 olmesartan medoxomil hydrochlorothiazide 53 Rheumatoid Arthritis Patients 53 ARCALYST ® 53 SELENA SLEDAI score 53 Severe Asthma 53 palmar plantar 53 Thromboembolic 53 cEVR 53 Acute Physiology 53 Apolipoprotein B 53 Scale EDSS score 53 ‰ ¥ 53 erythrocyte sedimentation rate 53 Inventory BPI 53 Posttraumatic 53 fatigue abdominal pain 53 SBM frequency 53 Deep Venous Thrombosis 53 atheroma volume 53 Bosentan 53 reflux esophagitis 53 Pelvic Organ Prolapse 53 Non Alcoholic Steatohepatitis 53 Shareholder Return 53 Mean Symptom Complex 53 Combination Treatment 53 Albuminuria 53 Treatment Outcome 53 Septic Shock 52 Anxiety Depression 52 Opioid Use 52 Study Demonstrates 52 Prognostic Value 52 Exacerbation 52 Significantly Improves 52 diabetic polyneuropathy 52 Bone Mineral Density 52 HbA 1c levels 52 subscore 52 Clinical Outcome 52 Chemotherapy Induced 52 extrapyramidal symptoms 52 -#.# mg dL [001] 52 FACIT Fatigue 52 vasomotor 52 PSQI 52 Posaconazole 52 LDL Cholesterol 52 Cognitive Function 52 hyperhomocysteinemia 52 Non inferiority 52 LV ejection fraction 52 autonomic dysfunction 52 Alzheimer Disease Assessment 52 posttreatment 52 Intraocular Pressure 52 DAS# [002] 52 Migraine Headaches 52 Hepatic Encephalopathy 52 Bosutinib 52 Sexual Desire 52 Catheter Associated 52 depressive symptom 52 Hemolysis 52 CFQ R 52 Platelet Aggregation 52 Adenomas 52 Demonstrate Significant 52 Glycemic Control 52 Demonstrates Efficacy 52 Hypotension 52 salmeterol fluticasone propionate 52 Angioedema 52 Benign Prostatic Hyperplasia 52 interrater reliability 52 Metastatic Prostate Cancer 52 HDL Cholesterol 52 nausea constipation 52 â ‰ ¥ 52 Coronary Artery Calcium 52 PCWP 52 Exhaled Nitric Oxide 52 Myocardial 52 corticosteroid dose 52 MMSE score 52 erection hardness 52 Clinical Relevance 52 haematologic 52 serologically active patients 52 Predictive Value 52 Allergic Rhinitis 52 ACR# response 52 Pearson correlation coefficient 52 function subscales 52 hematological parameters 52 Hormone Receptor Positive 52 NIS LL 52 Autologous Stem Cell Transplantation 52 Randomized Placebo Controlled Trial 52 Uterine 52 Partial Nephrectomy 52 Pulmonary Artery 52 FDA defined valvulopathy 52 Depressive Symptomatology 52 Sleep Apnea Treatment 52 fatigue asthenia 52 SSRI citalopram 52 Is Well Tolerated 52 Hamilton Rating Scale 52 Preoperatively 52 Diabetic Neuropathy 52 Cardiotoxicity 52 spirometric 52 See WARNINGS 52 BILAG 52 Reduces Pain 52 CLINICAL STUDIES 52 Assessment Scale 52 Community Acquired Pneumonia 52 unresectable HCC 52 interobserver reliability 52 Retreatment 52 erosive gastritis 52 Beta Blocker 52 sensory neuropathy 52 arterial oxygen saturation 52 Comorbid 52 Desvenlafaxine Succinate 52 Cronbach alpha 52 HRQL 52 moderate hepatic impairment 52 Lowers Risk 52 urinary albumin 52 Erosive Esophagitis 52 asthenia fatigue 52 intima media thickness 52 headache diarrhea nausea 52 Endocrine Therapy 52 Adverse Event 52 RECIST Response Evaluation Criteria 52 Renal Function 52 Rating Scale 52 Chemotherapy induced 52 dysmenorrhoea 52 Total Nasal Symptom 52 anemia thrombocytopenia 52 ANCOVA 52 Thrombus 52 diameter stenosis 52 Watchful Waiting 52 lactate dehydrogenase LDH 52 Erectile 52 ADAS Cog 52 ACE Inhibitors 52 Chronic Migraine 52 AUA BPH Symptom Score 51 plasma cortisol 51 ALT elevations 51 Treating Chronic 51 Inflammatory Response 51 Significantly Reduced 51 triiodothyronine 51 IPSS 51 ertapenem 51 Ischaemic 51 paraesthesia 51 Antihistamine 51 Significantly Reduces 51 glomerular filtration 51 Invasive Fungal Infections 51 Acidosis 51 Phase Ib Clinical Trial 51 cerebral oxygenation 51 Single Dose 51 urine albumin 51 Hb A1C 51 Pharmacodynamics 51 TLUS 51 subscales 51 Coronary Calcium 51 creatinine ratio 51 fasting plasma 51 GERD symptom 51 4mg/kg 51 Thymic 51 BMI z 51 MAXALT 51 Oesophageal 51 Low Testosterone 51 Resistant Hypertension 51 Cholesterol Levels 51 Ashworth Scale 51 Fibromyalgia Pain 51 carotid IMT 51 serum sodium levels 51 HAQ DI 51 APACHE II 51 baseline HbA1c 51 Therapy Reduces 51 Coronary Arteries 51 Paroxysmal 51 Capacity FVC 51 atrophic gastritis 51 vitreous haze 51 vitreous floaters 51 Hamilton Anxiety Scale 51 Rhinosinusitis 51 Placebo Controlled Trial 51 achieved statistical significance 51 Bacteremia 51 Reduce Mortality 51 WOMAC 51 Dizziness 51 prespecified secondary 51 Glucose Control 51 Menopause Symptoms 51 Detrol Detrol LA 51 Visual Analogue Scale 51 Iron Deficiency 51 Adjuvant Therapy 51 Thrombolysis 51 Predict Risk 51 Secondary efficacy endpoints 51 interquartile range IQR 51 Clinical Practice Guideline 51 STRIDE PD 51 FLOMAX 51 eosinophilia 51 Skin Irritation 51 odds ratios ORs 51 Iron Overload 51 diabetes mellitus DM 51 Chronic Insomnia 51 Interstitial Cystitis 51 Lung Injury 51 Metastatic Renal Cell Carcinoma 51 Virologic Response 51 Scale EDSS 51 depressive symptomatology 51 LAMICTAL 51 Endometrial Cancer 51 DAS# remission 51 nadroparin 51 constipation dizziness 51 Study Shows Significant 51 Prevent Stroke 51 antigen PSA levels 51 Bloodstream Infections 51 Vertebral Compression Fractures 51 glycated hemoglobin HbA1c 51 Embolism 51 Pain Rating Scale 51 nonsevere 51 Insertion Loss 51 MSLT 51 Intracranial 51 lowest tertile 51 somatic symptoms 51 chills fever headache 51 Floating Rate Debt 51 Secondary Hyperparathyroidism 51 total cholesterol triglycerides 51 vertigo dizziness 51 ST Elevation Myocardial 51 Levels Linked 51 Obese Patients 51 achieved ACR# 51 Atomoxetine 51 Left Ventricular 51 Antacids 51 Depression Scale 51 Abdominal Fat 51 Patellofemoral 51 Sexual Function 51 serum prostate 51 Histologic 51 diarrhea flatulence 51 Orthopedic Implants 51 gadolinium enhancing 51 ug ml 51 Cholesterol HDL 51 Functional Outcomes 51 hypovitaminosis D 51 Hemodynamic 50 Reduced Risk 50 hepatic cirrhosis 50 Hemoglobin A1c 50 detrusor 50 SUVmax 50 Stroke Scale NIHSS 50 ALT AST 50 Adalimumab 50 Reperfusion 50 Exacerbations 50 Non Inferiority 50 linaclotide treated 50 EQ 5D 50 Adjuvant Treatment 50 imiquimod cream 50 Intrathecal 50 serum folate concentrations 50 Infusion Reactions Severe 50 Physical Function 50 Oropharyngeal Candidiasis 50 Mortality Risk 50 Status Scale EDSS 50 Adjunctive 50 postprocedure 50 Thiazolidinediones 50 EDSS scores 50 Sleep Disturbances 50 BPRS 50 mcg linaclotide 50 #mg BID [001] 50 abdominal distension 50 Spinal Manipulation 50 ejaculatory function 50 HRQOL 50 HRQoL 50 CI #.#-#.# [001] 50 Outcome Measures 50 mRS 50 QVAR ® 50 perioperative mortality 50 chronic urticaria 50 Decitabine 50 ADAS cog 50 confidence intervals CIs 50 euthymic patients 50 gross hematuria 50 Score DAS# 50 Nonalcoholic Fatty Liver Disease 50 somnolence sleepiness 50 adrenal insufficiency 50 Contrast Agent 50 neurocognitive function 50 Infarct 50 moderately emetogenic 50 Minimally Invasive Treatment 50 Comorbidity 50 Visceral Fat 50 Protease Inhibitors 50 Gastritis 50 exploratory endpoints 50 preoperative PSA 50 bronchoalveolar lavage 50 Hepatitis C Genotype 50 frequent awakenings 50 LPS induced 50 Prostate Specific Antigen 50 artery occlusion 50 Musculo Skeletal Disorders 50 systemic corticosteroid 50 Soft Tissue Sarcoma 50 Investigational Agent 50 Fasting plasma glucose 50 Randomized Evaluation 50 constipation nausea 50 Muscle Pain 50 serum urate 50 Impaired loans 50 HCV Genotype 50 neutropenia dehydration dyspnea 50 abnormal ejaculation 50 % CI #.#-#.# [007] 50 Iron Deficiency Anemia 50 hyperhydrosis 50 variance ANOVA 50 Pharmacodynamic 50 Node Negative 50 dermatologic reactions 50 hyperlipidaemia 50 Hip Fracture 50 hemorrhagic pancreatitis 50 Secondary endpoints included 50 Osteomyelitis 50 Dose Response 50 QoL 50 Irritable Bowel 50 Restless Legs 50 urinary cortisol 50 radicular pain 50 serum lipid levels 50 Unfractionated Heparin 50 Effective Treatments 50 intraclass correlation coefficient 50 thickness CIMT 50 protein excretion 50 Subtype 50 myalgia arthralgia 50 NIHSS 50 mU liter 50 Blepharospasm 50 Stent Placement 50 elevated creatinine 50 nonfatal myocardial infarction MI 50 Stroke Scale 50 atrioventricular block 50 gastro oesophageal reflux 50 ETDRS 50 Percutaneous Tibial Nerve Stimulation 50 giant cell arteritis 50 Prostatic 50 Uric Acid 50 bullous 50 extrapyramidal 50 DAS# scores 50 Reduces Mortality 50 HeFH 50 Antiplatelet 50 fatigue headache nausea 50 binary restenosis 50 fasting insulin 50 fructose intolerance 50 Creatinine 50 State Trait Anxiety 50 Platinol ® 50 Liver Failure 50 deep venous thromboses 50 Demonstrates Significant 50 Hepatotoxicity 50 REYATAZ r arm 50 Measurement Uncertainty 50 diarrhea nausea fatigue 50 Psychosomatic Research 50 metastatic carcinoid tumors 50 Often Misdiagnosed 50 fatal anaphylactic 50 muscle aches fatigue 50 Randomized Controlled 50 Fluticasone Propionate 50 Retinal Vein Occlusion 50 Clinically meaningful 50 angiographic restenosis 50 SELENA SLEDAI 50 Scale cognitive subscale 50 leukocyte count 50 Hematologic 50 echocardiographic parameters 50 nausea emesis 50 COPD Exacerbations 50 Reflux Disease 50 hyperreflexia 50 dizziness nausea diarrhea 50 nitroprusside 50 Healthy Behavior 50 EDSS score 50 Antibody Therapy 50 Atrophic 50 Injury Severity Score 50 Postoperative Ileus 50 Patients Suffering 50 transcranial Doppler ultrasound 50 Glomerular Filtration Rate 50 Contrast Agents 50 affective psychosis 50 Risk Stratification 50 Hypertrophic 50 Demonstrates Statistically Significant 50 Psychodynamic Psychotherapy 49 hepatic enzyme 49 Vertebral Fractures 49 SF #v# 49 elevated lipase 49 Allergy Sinus 49 sUA 49 FluCAM arm 49 Axillary 49 Generalized Anxiety Disorder GAD 49 comorbid depression 49 pharyngolaryngeal pain 49 Severity 49 Lesion 49 Benzoyl Peroxide 49 Tyrosine Kinase Inhibitor 49 Skin Lesions 49 Sleepiness 49 Cardiogenic Shock 49 mean baseline A1C 49 Quotient TM 49 Thrombocytopenia 49 Wakefulness Test 49 State Examination MMSE 49 left ventricular diastolic 49 Ranolazine 49 achieving PASI 49 Depression Anxiety 49 Parnate 49 symptomatic intracranial hemorrhage 49 Monotherapy 49 Pooled Analysis 49 diaphoresis 49 Neovascularization 49 Insulin Secretion 49 Dehydrogenase 49 COPD exacerbation 49 Reduces Risk 49 Carotid Artery Stenting 49 Dose Reduction 49 Diuretic 49 Novel Compound 49 CLINICAL PHARMACOLOGY 49 Aortic Stenosis 49 Follicular Lymphoma 49 Clinical Efficacy 49 ACTEMRA TM 49 total cholesterol LDL 49 PsA 49 Medication Adherence 49 nerve conduction velocity 49 hemoglobin A1c HbA1c 49 R adefovir dipivoxil 49 Invasive Breast Cancer 49 Insulin Glargine 49 Drug Prevents 49 intraclass correlation coefficients 49 Symptom Improvement 49 undetectable HBV DNA 49 Predict Response 49 Pelvic Pain 49 somnolence fatigue 49 Electrical Stimulation 49 Patient Satisfaction 49 Cost Effectiveness 49 Polycystic ovary syndrome PCOS 49 Abbott HUMIRA 49 Exercise Induced 49 Venous thromboembolism 49 apnea hypopnea 49 Prospective Randomized 49 carotid intima media 49 Cardiovascular Disease Risk 49 apnea hypopnea index 49 Study Evaluating 49 Helps Relieve 49 NNT = 49 knee arthroplasty 49 PENNSAID 49 Carotid Endarterectomy 49 D Dimer 49 CIN2 + 49 Guidelines Issued 49 Heart Rate Variability 49 Surgical Procedures 49 p = ns 49 Dilatation 49 overactive bladder syndrome 49 Alanine 49 Atrial 49 ecchymosis 49 abdominal adiposity 49 Clinically Tested 49 P = .# 49 chills headache 49 regression coefficient 49 Bronchodilator 49 bioavailable testosterone 49 Study Showed 49 p = .# [001] 49 subjective sleepiness 49 angiotensin II receptor blockers 49 #q# deletion syndrome 49 Clinical Outcomes 49 Viral Load 49 Eye Infections 49 Univariate analysis 49 Trigeminal Neuralgia 49 Asthma Treatment 49 Strongly Linked 49 Telithromycin 49 Subgroup Analysis 49 pooled comparator 49 DLQI 49 somatization disorder 49 receiving PEGINTRON 49 Novel Inhibitor 49 somnolence sedation 49 Brain Metastases 49 comorbid anxiety 49 diarrhea dyspepsia 49 Am Soc Nephrol 49 Stent thrombosis 49 Viral load 49 MADRS scores 49 serum PSA 49 Cyclooxygenase 2 49 B Cell Lymphoma 49 TMP SMX 49 Osteoarthritis Knee Pain 49 Premature Ejaculation 49 univariate analyzes 49 Beta Amyloid 49 Retention Rate 49 Hippocampal 49 hemorrhagic cystitis 49 analgesic efficacy 49 paraprotein 49 Radiation Dose 49 FDA Approves Drug 49 abdominal pain headache 49 Non Alcoholic Fatty 49 Hormone Refractory Prostate Cancer 49 Diabetic neuropathy 49 serum estradiol 49 Vitamin D Linked 49 hypercholesterolaemia 49 ADCS ADL 49 Peripheral Vascular Disease 49 covariance ANCOVA 49 Squamous Cell Carcinoma 49 Disease Progression 49 somnolence headache 49 nausea diarrhea fatigue 49 reflux disease GERD 49 serum triglycerides 49 salivary cortisol 49 Plus Ribavirin 49 mild renal insufficiency 49 NIHSS score 49 Suboptimal 49 Radiation Exposure 49 Hypoglycemia 49 serum phosphate 49 Ventricular Tachycardia 49 AUA Symptom Score 49 Diabetic Nephropathy 49 Intravenous immunoglobulin 49 Neoplasms 49 cardiovascular cerebrovascular 49 hepatic enzymes 49 Female Sexual Function 49 receiving XGEVA 49 multivariable analysis 49 Impressions Improvement 49 psychosocial functioning 49 Complete Remission 49 glycated hemoglobin 49 impaired glucose metabolism 49 serum ferritin 49 AST ALT 49 cortical atrophy 49 Immune Responses 49 Hypersensitivity 49 albumin excretion 49 Hormonal Therapy 49 sensitivity specificity 49 Cognitive dysfunction 49 Cerebellar 49 hemodynamic variables 49 Clinical Remission 49 mmHg p = 49 Cardiorespiratory fitness 49 Survival Rate 49 Inflammatory Pain 49 Blood Glucose Testing 49 DETROL LA 49 Acute sinusitis 49 Topical Cream 49 nasopharyngitis constipation dyspepsia 49 intraobserver 49 bone marrow reticulin deposition 49 Prognostic 49 Advanced Colorectal Cancer 49 Coronary Artery Bypass Surgery 49 #-# Full Text 49 Stenosis 49 Nausea vomiting 49 Allergic Conjunctivitis 49 Dyslipidemia 49 Hypertrophy 49 Otitis Media 49 angioneurotic edema 49 gait disturbances 49 ALS Functional 49 Operative mortality 49 Growth Hormone Deficiency 49 dactylitis 49 trough FEV1 49 Platelet counts 49 metabolic alkalosis 49 Urine Test 48 Eszopiclone 48 Mg Uk 48 EBMT criteria 48 timolol maleate 48 diarrhea nausea vomiting 48 dizziness sleepiness 48 Diabetic Foot Ulcer 48 ICD shocks 48 Antidepressants Linked 48 Help Predict 48 McGill Pain Questionnaire 48 r2 = 48 Phase IIa Clinical Trial 48 Index FSFI 48 Cervical Dystonia 48 antibiotics metronidazole 48 Gastroparesis 48 gastro esophageal reflux 48 Diastolic Heart Failure 48 Depression Rating Scale 48 Fecal Incontinence 48 Bronchiectasis 48 hyperresponsiveness 48 Sexual Satisfaction 48 Healthy Behaviors 48 PENTASA 48 hemoglobin A1C 48 CONTRAINDICATIONS 48 Schizophrenia Treatment 48 highest tertile 48 Liver Injury 48 Adjunctive Therapy 48 Lipid Profile 48 Captopril 48 Medication Errors 48 Prognostic Index 48 Cognitive Abilities 48 Numoisyn Liquid 48 maximal treadmill 48 nimodipine 48 abnormal cytology 48 Glasgow Coma Scale